SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the appointment of Matt Valentino as Chief People Officer. Before joining ShapeTX, Matt was at the helm of diverse People teams for notable biotech and technology companies including Calico Labs, Genentech, Pandora, Validant, and DoorDash.

2024年5月2日，西雅图（环球通讯社）--Shape Therapeutics Inc.（ShapeTX）是人工智能和RNA编辑相结合以彻底改变基因组医学的领导者，很高兴宣布任命马特·瓦伦蒂诺为首席人事官。在加入ShapeTX之前，Matt曾为著名的生物技术和技术公司（包括Calico Labs、Genentech、Pandora、Validant和DoorDash）领导多人团队。

“Matt brings extensive experience in leading teams at scientific R&D companies focused on drug development, manufacturing, robotics, and AI/ML applications. As an early team member at Calico Labs, he played a crucial role in scaling the company from 70 to over 300 employees, including the expansion of their Drug Discovery, Computational and Clinical Development teams.

“马特在专注于药物开发、制造、机器人技术和AI/ML应用的科学研发公司的领导团队中拥有丰富的经验。作为Calico实验室的早期团队成员，他在将公司从70名员工扩大到300多名员工方面发挥了关键作用，包括扩大其药物发现、计算和临床开发团队。

While at DoorDash, Matt facilitated growth from 2,000 to over 17,000 global employees. His expertise will be instrumental in guiding ShapeTX through its next growth phase as we continue to innovate at the intersection of technology and biotechnology,' said Francois Vigneault, Ph.D., Co-Founder and CEO of ShapeTX.

在DoorDash任职期间，Matt促进了全球员工从2000人增长到17000多人。ShapeTX联合创始人兼首席执行官弗朗索瓦·维尼奥（FrancoisVigneault）博士说，随着我们在技术和生物技术的交叉点不断创新，他的专业知识将有助于指导ShapeTX进入下一个增长阶段。

'We are confident in Matt's leadership and excited about the future developments he will drive at ShapeTX.' Matt added, 'I’m thrilled to join the talented team at ShapeTX, and I am eager to advance our mission of repairing genetic causes of disease with programmable RNA medicines.' About ShapeTXShape Therapeutics operates at the convergence of AI and RNA editing to revolutionize genomic medicine.

“我们对马特的领导能力充满信心，并对他将在ShapeTX推动的未来发展感到兴奋。”马特补充道，“我很高兴加入ShapeTX的天才团队，我渴望推进我们用可编程RNA药物修复疾病遗传原因的使命。”关于ShapeTXShape Therapeutics在AI和RNA编辑的融合中运作，以彻底改变基因组医学。

Our proprietary RNA editing technology, RNAfix®, represents a significant leap forward over CRISPR-based tools, achieving 95% editing efficiency in vivo, and a path to one-time curative treatments for thousands of diseases. With over 90 million laboratory-validated guide RNA data points.

我们专有的RNA编辑技术RNAfix®代表了对基于CRISPR的工具的重大飞跃，在体内实现了95%的编辑效率，并为数千种疾病提供了一次性治疗的途径。拥有超过9000万个经过实验室验证的指导RNA数据点。